Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)
A global pharmaceutical company, which produces pharmaceutical ingredients and intermediates, finished dosage forms and biotechnology products and markets them globally. It conducts research in the areas of cancer, diabetes, cardiovascular disease etc.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Tremendous growth stock
Recs
drugs are where its at
Recs
Rapid expansion through acquisitions, more and more US FDA approvals and vast range of molecules under research at different levels.
Recs
A GREAT LOW PRICE DRUG PRODUCER.
MEDICINES IN INDIA ARE UNBELIEVABLY CHEAP, THIS STOCK WILL NOT MISS TO GROWWW.
Recs
Market leader in Indian pharmaceuticals. Making good headway in the US market. Solid research and studies management.
Recs
Low cost generic drugs are already a huge market and it will get bigger. Huge revenue growth rates. Plenty of room for growth in this area.
Recs
Democrats in power = cheaper drugs
Recs
Great Drug Company
Recs
Merck is outsourcing some of it generic drugs to Reddy. Relationship made in heaven.
Recs
Indian pharma is growing & RDY is in lead...
Recs
Small and good management. They have already a broad product line. will be volatile!
Recs
Invest in India early for big gains.
Recs
i anticipate results continuing to impress. Analysts expectations mean nothing because of the acquisitions so management feeds the PR machine with information they later impress with. A bigger and bigger story easy to manipulate and as they get better at coopying and get better relationships with the bigger players - snowball spring to mind.
Recs
India will be a force in the pharma field in the future and there are indications that it already is (i.e. generics). This company is well positioned to be a frontrunner
Recs
I want to explore this company further before investing in it, but at first glance I like it.
Recs
huge upside...
Recs
RDY or Dr. Reddy's Laboratories is an Indian company that is a generic drug and API (active pharmaceutical ingredient )manufacturer. In 2005 and 2006, a lot of the patents owned by large US pharmaceuticals have come off the patent protection. This opens the doors for generic drug manufacturers to produce similar drugs at much lower prices. This is an emerging market company that is listed in NYSE - as part of our continuing analyis of emerging market segment, we will look at this company in more detail.
Recs
undervalued at this price
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 61 - 78 of 78 : « Previous 1 2 3 4